TRANSLATIONAL LUNG CANCER RESEARCH : Impact Factor & More
eISSN: 2226-4477pISSN: 2218-6751
Share this on:
Key Metrics
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on TRANSLATIONAL LUNG CANCER RESEARCH
TRANSLATIONAL LUNG CANCER RESEARCH Journal Specifications
| Overview | |
| Publisher | AME PUBLISHING COMPANY |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 2012 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in TRANSLATIONAL LUNG CANCER RESEARCH ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in TRANSLATIONAL LUNG CANCER RESEARCH
Lightweight hybrid foundation model for lung cancer prognosis based on low-dose chest X-ray images.
- 1 Mar 2026
- Translational lung cancer research
Advances in the research on radiotherapy for lung cancer: a 2025 review.
- 1 Mar 2026
- Translational lung cancer research
B cell-driven refractory hemocytopenia in immune checkpoint inhibitor therapy: a report of two cases.
- 1 Mar 2026
- Translational lung cancer research
Adjuvant chemotherapy for completely resected stage IB-IIA non-small cell lung cancer according to the AJCC 8th edition staging system: a real-world retrospective cohort study based on the SEER database.
- 1 Mar 2026
- Translational lung cancer research
Effectiveness and safety of combination immunotherapy with or without ipilimumab according to PD-L1 expression in patients with non-small cell lung cancer: a multi-center retrospective cohort study.
- 1 Mar 2026
- Translational lung cancer research
Neoadjuvant or conversion anti-PD-1/PD-L1 immunotherapy combined with chemotherapy improves 2-year survival and achieves high pathological complete response rate in patients with stage IIB-IIIB small-cell lung cancer.
- 1 Mar 2026
- Translational lung cancer research
Lightweight hybrid foundation model for lung cancer prognosis based on low-dose chest X-ray images.
- 1 Mar 2026
- Translational lung cancer research
Advances in the research on radiotherapy for lung cancer: a 2025 review.
- 1 Mar 2026
- Translational lung cancer research
B cell-driven refractory hemocytopenia in immune checkpoint inhibitor therapy: a report of two cases.
- 1 Mar 2026
- Translational lung cancer research
Adjuvant chemotherapy for completely resected stage IB-IIA non-small cell lung cancer according to the AJCC 8th edition staging system: a real-world retrospective cohort study based on the SEER database.
- 1 Mar 2026
- Translational lung cancer research
Effectiveness and safety of combination immunotherapy with or without ipilimumab according to PD-L1 expression in patients with non-small cell lung cancer: a multi-center retrospective cohort study.
- 1 Mar 2026
- Translational lung cancer research
Neoadjuvant or conversion anti-PD-1/PD-L1 immunotherapy combined with chemotherapy improves 2-year survival and achieves high pathological complete response rate in patients with stage IIB-IIIB small-cell lung cancer.
- 1 Mar 2026
- Translational lung cancer research
FAQs on TRANSLATIONAL LUNG CANCER RESEARCH
How long has TRANSLATIONAL LUNG CANCER RESEARCH been actively publishing? 
What is the publishing frequency of TRANSLATIONAL LUNG CANCER RESEARCH?
How many articles did TRANSLATIONAL LUNG CANCER RESEARCH publish last year?
What is the eISSN & pISSN for TRANSLATIONAL LUNG CANCER RESEARCH?
Who is the publisher of TRANSLATIONAL LUNG CANCER RESEARCH?
